Provided By GlobeNewswire
Last update: Feb 11, 2025
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.
Read more at globenewswire.comNASDAQ:PMVP (10/17/2025, 8:00:01 PM)
1.4
-0.04 (-2.78%)
Find more stocks in the Stock Screener